Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma.

Rue SM, Eckelman BP, Efe JA, Bloink K, Deveraux QL, Lowery D, Nasoff M.

Vet Immunol Immunopathol. 2015 Apr 15;164(3-4):148-59. doi: 10.1016/j.vetimm.2015.02.004. Epub 2015 Feb 18.

PMID:
25764941
2.

Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function.

Kwiatkowski N, Jelluma N, Filippakopoulos P, Soundararajan M, Manak MS, Kwon M, Choi HG, Sim T, Deveraux QL, Rottmann S, Pellman D, Shah JV, Kops GJ, Knapp S, Gray NS.

Nat Chem Biol. 2010 May;6(5):359-68. doi: 10.1038/nchembio.345. Epub 2010 Apr 11.

3.

A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function.

Rottmann S, Wang Y, Nasoff M, Deveraux QL, Quon KC.

Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15195-200. Epub 2005 Oct 6.

4.

RNAi and HTS: exploring cancer by systematic loss-of-function.

Willingham AT, Deveraux QL, Hampton GM, Aza-Blanc P.

Oncogene. 2004 Nov 1;23(51):8392-400. Review.

PMID:
15517021
5.

Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle.

Ren YG, Wagner KW, Knee DA, Aza-Blanc P, Nasoff M, Deveraux QL.

Mol Biol Cell. 2004 Nov;15(11):5064-74. Epub 2004 Sep 8.

6.

Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin.

Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J, Hofmann F, Deveraux QL, Hampton GM.

Oncogene. 2004 Aug 26;23(39):6621-9.

PMID:
15208666
7.

Caspase-2 can function upstream of bid cleavage in the TRAIL apoptosis pathway.

Wagner KW, Engels IH, Deveraux QL.

J Biol Chem. 2004 Aug 13;279(33):35047-52. Epub 2004 Jun 1.

8.

Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway.

Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC.

Cancer Cell. 2004 May;5(5):501-12.

9.

Activation and suppression of the TRAIL death-receptor pathway in chemotherapy sensitive and resistant follicular lymphoma cells.

Wagner KW, King F, Nomoto K, Knee DA, Hampton G, Nasoff M, Deveraux QL.

Cancer Biol Ther. 2003 Sep-Oct;2(5):534-40.

PMID:
14614322
10.

Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAi.

Deveraux QL, Aza-Blanc P, Wagner KW, Bauerschlag D, Cooke MP, Hampton GM.

Semin Cancer Biol. 2003 Aug;13(4):293-300. Review.

PMID:
14563124
11.

Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening.

Aza-Blanc P, Cooper CL, Wagner K, Batalov S, Deveraux QL, Cooke MP.

Mol Cell. 2003 Sep;12(3):627-37.

12.

Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction.

Wu TY, Wagner KW, Bursulaya B, Schultz PG, Deveraux QL.

Chem Biol. 2003 Aug;10(8):759-67.

PMID:
12954335
13.

ILPIP, a novel anti-apoptotic protein that enhances XIAP-mediated activation of JNK1 and protection against apoptosis.

Sanna MG, da Silva Correia J, Luo Y, Chuang B, Paulson LM, Nguyen B, Deveraux QL, Ulevitch RJ.

J Biol Chem. 2002 Aug 23;277(34):30454-62. Epub 2002 Jun 4.

14.

IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition.

Sanna MG, da Silva Correia J, Ducrey O, Lee J, Nomoto K, Schrantz N, Deveraux QL, Ulevitch RJ.

Mol Cell Biol. 2002 Mar;22(6):1754-66.

15.

Antiapoptotic proteins. The bcl-2 and inhibitor of apoptosis protein families.

Deveraux QL, Schendel SL, Reed JC.

Cardiol Clin. 2001 Feb;19(1):57-74. Review.

PMID:
11787814
16.

Cloning and characterization of an inhibitor of apoptosis protein (IAP) from Bombyx mori.

Huang Q, Deveraux QL, Maeda S, Stennicke HR, Hammock BD, Reed JC.

Biochim Biophys Acta. 2001 Jan 15;1499(3):191-8.

17.

TRAF1 is a substrate of caspases activated during tumor necrosis factor receptor-alpha-induced apoptosis.

Leo E, Deveraux QL, Buchholtz C, Welsh K, Matsuzawa S, Stennicke HR, Salvesen GS, Reed JC.

J Biol Chem. 2001 Mar 16;276(11):8087-93. Epub 2000 Nov 29.

18.

Response

Reed JC, Matsuyama S, Deveraux QL, Llopis J, Tsien R.

Nat Cell Biol. 2000 Oct;2(10):E172-3. No abstract available.

PMID:
11025672
19.

Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells.

Blanc C, Deveraux QL, Krajewski S, Jänicke RU, Porter AG, Reed JC, Jaggi R, Marti A.

Cancer Res. 2000 Aug 15;60(16):4386-90.

20.

Purification and use of recombinant inhibitor of apoptosis proteins as caspase inhibitors.

Deveraux QL, Welsh K, Reed JC.

Methods Enzymol. 2000;322:154-61. No abstract available.

PMID:
10914012
21.

Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis.

Matsuyama S, Llopis J, Deveraux QL, Tsien RY, Reed JC.

Nat Cell Biol. 2000 Jun;2(6):318-25.

PMID:
10854321
22.

Evolutionary conservation of apoptosis mechanisms: lepidopteran and baculoviral inhibitor of apoptosis proteins are inhibitors of mammalian caspase-9.

Huang Q, Deveraux QL, Maeda S, Salvesen GS, Stennicke HR, Hammock BD, Reed JC.

Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1427-32.

23.

Endogenous inhibitors of caspases.

Deveraux QL, Stennicke HR, Salvesen GS, Reed JC.

J Clin Immunol. 1999 Nov;19(6):388-98. Review.

PMID:
10634212
24.

Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases.

Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC.

EMBO J. 1999 Oct 1;18(19):5242-51.

25.

Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia.

Krajewski S, Krajewska M, Ellerby LM, Welsh K, Xie Z, Deveraux QL, Salvesen GS, Bredesen DE, Rosenthal RE, Fiskum G, Reed JC.

Proc Natl Acad Sci U S A. 1999 May 11;96(10):5752-7.

26.

Caspase-9 can be activated without proteolytic processing.

Stennicke HR, Deveraux QL, Humke EW, Reed JC, Dixit VM, Salvesen GS.

J Biol Chem. 1999 Mar 26;274(13):8359-62.

27.

IAP family proteins--suppressors of apoptosis.

Deveraux QL, Reed JC.

Genes Dev. 1999 Feb 1;13(3):239-52. Review. No abstract available.

28.

IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases.

Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC.

EMBO J. 1998 Apr 15;17(8):2215-23.

29.

The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases.

Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC.

EMBO J. 1997 Dec 1;16(23):6914-25.

30.

X-linked IAP is a direct inhibitor of cell-death proteases.

Deveraux QL, Takahashi R, Salvesen GS, Reed JC.

Nature. 1997 Jul 17;388(6639):300-4.

PMID:
9230442

Supplemental Content

Loading ...
Support Center